Trexquant Investment LP Grows Stake in AnaptysBio, Inc. $ANAB

Key Points

• Trexquant Investment LP increased its stake in AnaptysBio by 152.9% during the first quarter, owning 153,563 shares valued at approximately $2.86 million.
• Several other hedge funds also boosted their holdings in AnaptysBio, with increases ranging from 126.5% to 9,778.9% during the same period.
• AnaptysBio reported earnings of ($1.34) EPS, surpassing analysts' expectations, with revenue of $22.26 million for the quarter.

Trexquant Investment LP grew its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 152.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 153,563 shares of the biotechnology company's stock after buying an additional 92,843 shares during the period. Trexquant Investment LP owned 0.52% of AnaptysBio worth $2,855,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in AnaptysBio by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock worth $880,000 after purchasing an additional 528 shares in the last quarter. Rhumbline Advisers lifted its holdings in AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock worth $574,000 after purchasing an additional 826 shares in the last quarter. US Bancorp DE lifted its holdings in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares in the last quarter. California State Teachers Retirement System lifted its holdings in AnaptysBio by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company's stock worth $193,000 after purchasing an additional 1,359 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares in the last quarter.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the completion of the sale, the director owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 33.50% of the company's stock.

AnaptysBio Stock Performance

ANAB stock traded down $0.09 during trading on Tuesday, hitting $22.10. 87,544 shares of the company traded hands, compared to its average volume of 736,659. The firm has a market capitalization of $618.80 million, a PE ratio of -4.93 and a beta of -0.19. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $40.70. The company has a 50-day moving average of $23.13 and a 200-day moving average of $20.96.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.50) by $0.16. The company had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. Sell-side analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. UBS Group restated a "neutral" rating and issued a $20.00 target price (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and increased their price objective for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. Wedbush increased their price objective on AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Finally, Guggenheim reiterated a "buy" rating and set a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $46.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.